In this edition of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, interviews Alessio Travaglia, PhD, PMP, director, Translational Science, Neuroscience, at the Foundation for the National Institutes of Health (FNIH).   The wide-ranging interview tackles all aspects of Alzheimer’s testing and treatment, including: Why traditional methods of Alzheimer’s testing are expensive, invasive, and limit access.The benefits of blood-based biomarkers for Alzheimer’s diagnosis.How better diagnostics will benefit patients.Why we’re on the cusp of a new golden age of neurologyHow more biomarkers fuel not only better diagnostics but better treatments.